Olema is currently developing a "cancer" drug that suppresses the body's production of Estrogen. Now this could be useful for breast cancer treatment but the real target audience, in my opinion, is hormone replacement therapy for gender transition. I don't necessarily endorse this kind of product but given the corporate and governmental policies surrounding the issue, I believe it could definitely be a very good financial opportunity. I charted this about a month ago and it has moved even more aggressively than I expected. This could be because this type of product, I imagine, would have to be developed under the current administration.
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of targeted therapies for women's cancers. It also focuses on developing therapies for the treatment of breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA. The listed name for OLMA is Olema Pharmaceuticals, Inc. Common Stock
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of targeted therapies for women's cancers. It also focuses on developing therapies for the treatment of breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA. The listed name for OLMA is Olema Pharmaceuticals, Inc. Common Stock
